2011
DOI: 10.15373/2249555x/feb2014/131
|View full text |Cite
|
Sign up to set email alerts
|

Quantification of Immunity Status of Dabur Chyawanprash - A Review Part-1 (Experimental Studies)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…On treating dendritic cells with CP, a significant increase in the secretions of tumor necrosis factor-alpha (TNF-α) and macrophage inflammatory protein-1 alpha (MIP-1α), stimulation in interleukin-1 beta (IL-1β) levels, and rise in phagocytic activity were observed. The augmented immunity marker levels (TNF-α, IL-1β, and MIP1α), as well as enhancement of NK cells and phagocytic activity support the immunomodulatory properties of CP [117]. Clinical studies also support the immune-booster role of CP as demonstrated by reduced disease symptoms of seasonal influences, modulated IgE and immunity markers C3 and C4 levels, improved pulmonary functions, decreased cortisol levels, and increased quality of life (QoL) [118].…”
Section: Health Benefitsmentioning
confidence: 99%
“…On treating dendritic cells with CP, a significant increase in the secretions of tumor necrosis factor-alpha (TNF-α) and macrophage inflammatory protein-1 alpha (MIP-1α), stimulation in interleukin-1 beta (IL-1β) levels, and rise in phagocytic activity were observed. The augmented immunity marker levels (TNF-α, IL-1β, and MIP1α), as well as enhancement of NK cells and phagocytic activity support the immunomodulatory properties of CP [117]. Clinical studies also support the immune-booster role of CP as demonstrated by reduced disease symptoms of seasonal influences, modulated IgE and immunity markers C3 and C4 levels, improved pulmonary functions, decreased cortisol levels, and increased quality of life (QoL) [118].…”
Section: Health Benefitsmentioning
confidence: 99%
“…Till now, CP has been clinically studied in diverse population in various therapeutic targets, as a preventive as well as curative preparation and as an adjunct/add on therapy or monotherapy. In animal toxicity studies (acute-dose oral toxicity, 28 days repeated-dose oral toxicity studies, and 90 days repeated-dose oral toxicity studies), CP was found to be safe in the recommended dosage for the de ned period of time as no toxicity or bodyweight loss was found with all animals surviving throughout the study duration [7].…”
Section: Age Dosage and Duration Considerations In Cp Usagementioning
confidence: 96%